Phaseline

Targets › CYP46A1

CYP46A1 (Cholesterol 24-hydroxylase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Apr 2028.

P450 monooxygenase that plays a major role in cholesterol homeostasis in the brain. Primarily catalyzes the hydroxylation (with S stereochemistry) at C-24 of cholesterol side chain, triggering cholesterol diffusion out of neurons and its further degradation. (UniProt, Q9Y6A2)

Open in Phaseline: the race on CYP46A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AskBio France, SAS, a subsidiary of AskBioAB-1001 (AAVrh10.CAG.hCYP46A1)
AAV-mediated gene delivery of human cholesterol 24-hydroxylase (CYP46A1)
CYP46A1Phase 1Huntington DiseaseApr 2028

Conditions

Huntington Disease (1)

Modalities

other (1)

Companies

AskBio France, SAS, a subsidiary of AskBio (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.